WAWaldeir José de Almeida

Waldeir José de Almeida

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Waldeir José de Almeida has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of artificial intelligence on breast care pathways and future perspectives

    by Virgínia de Assis Silva, Renata Capanema Saliba Franco, Anna Dias Salvador, Waldeir José de Almeida, Gabriel Oliveira Bernardes Gil, Bernardo Bacelar de Faria, Jairo Luiz Coelho, José Tadeu Campos Avelar

    Artificial intelligence (AI) is a sophisticated technology already established in medicine. In mastology, there is robust evidence of the ability of AI software to optimize screening, reduce interval cancer rates, and decrease patient recall rates. In addition, AI provides parameters for predicting surgical complications and oncological therapeutic outcomes. Considering the rise of AI, this article aimed to conduct an integrative review, highlighting its main tools developed in mastology. A search was performed on the United States National Library of Medicine (PubMed) platform, using descriptors associated with AI and breast cancer. Retrospective studies, systematic reviews, and prospective clinical studies published in English in the last ten years were included. The results were organized by thematic areas and summarized in a table and the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) flowchart. Data analysis showed a concentration of information in the area of imaging — with advances in radiomics — and a still incipient, albeit promising, development in areas such as genetics and surgery. The article highlights the need for discussion on the ethical issues surrounding the implementation of AI. The reliability of data collection and manipulation must be guaranteed, and data automation should not imply automation of conduct, since medical responsibility in patient care is perennial.

  • Open Access

    Should the use of hormones for contraception and during menopause be contraindicated in women with high-penetrance mutations?

    by Virginia de Assis Silva, Waldeir José de Almeida, Arthur Chaves de Almeida, Letícia Martins de Araújo Campos Linhares

    Medical genetics is one of the fields with the greatest advancements in medical knowledge. The discovery of genes that determine greater susceptibility to certain neoplasms has motivated a vast amount aimed at determining the best management of patients with these mutations. The use of hormones, both as contraception and during menopause, for these women is a subject of ongoing debate — given their involvement in the pathophysiology of breast neoplasia. This article, therefore, aims to review the available literature on the topic. Thirteen publications were selected for narrative review. Regarding contraception, individualized assessment of these patients is still paramount in indicating hormonal contraception, with no formal contraindication to its use for patients with high-penetrance mutations. Regarding hormone therapy (HT), there are also no absolute contraindications. Consideration is only given to patients who have not undergone mastectomy. In such cases, HT can be considered for short periods, ideally using micronized progesterone in patients with a uterus.

  • Open Access

    Is the use of a dermal matrix mandatory in breast reconstruction with prosthesis after radiotherapy?

    by Jessica Mendes Costa de Freitas Santos, Virginia de Assis Silva, Waldeir José de Almeida, Arthur Chaves de Almeida

    Breast reconstruction is a crucial step in the treatment of breast cancer, allowing not only the restoration of body shape but also a significant improvement in patients' quality of life. However, choosing the ideal technique is a multifactorial challenge that requires consideration of several anatomical and clinical aspects. During the Northeast Mastology Conference held in September 2024 in Natal, it was agreed by consensus that the use of a dermal matrix (ADM) is not mandatory in breast reconstruction with prosthesis after radiotherapy.